BIOCONBiocon

₹380.5+0.89%

Market Cap

₹49,735.05 Cr

Stock P/E

129.18

ROCE

7.43%

ROE

7.03%

Book Value

₹193.03

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Foreign Investors

Domestic Investors

Public

From Last Concall

POSITIVES

•
Regulatory milestones and product launches expanding biosimilars footprint
•
Strategic balance-sheet strengthening via equity fundraising

NEGATIVES

•
Near-term margin headwinds from capital expenditure and fixed costs
•
High debt burden at Biocon Biologics weighing on the balance sheet

Peers Summary

Sector Leader

Biocon Ltd. shows moderate growth and profitability metrics compared to its peers but lags in efficiency and valuation attractiveness. Companies like Cipla and Dr. Reddy's Laboratories demonstrate superior profitability and valuation metrics, while Biocon's higher PE ratio indicates it may be overvalued relative to its peers.

Key Points

• Biocon has a moderate revenue growth of 3.43% YoY but strong 3-year growth of 27.36%.
• Cipla and Dr. Reddy's Laboratories are standout performers in profitability and valuation metrics.
• Cipla's low PE ratio (23.73) and high ROE (16.63%) make it a strong value pick.

Top Performers

Cipla Ltd.

Lowest PE ratio (23.73) and highest ROA (13.59%), making it attractive for both growth and value.

Dr. Reddy's Laboratories Ltd.

Strong profitability with a ROE of 21.76% and a very low PEG ratio (0.19), indicating it is undervalued.

Mankind Pharma Ltd.

Highest revenue growth of 18.12% YoY and strong profitability metrics.

Explore

Watchlists

Command Palette